Oral GLP-1 Drugs Quiet Brain Reward Circuit in Mice, Curbing Pleasure-Driven Eating

Overview

• An NIH-funded University of Virginia team reports in Nature that next-generation oral GLP-1 drugs suppressed hedonic, or pleasure-driven, eating in gene-edited mice by acting deep in the brain.
• Researchers gave orforglipron or danuglipron and saw activity move from the hindbrain to the central amygdala, which then dampened dopamine release in key reward hubs tied to wanting high-calorie foods.
• The team humanized mouse GLP-1 receptors to better model patient biology and mapped this reward pathway as distinct from the well-known hunger circuits in the hypothalamus and hindbrain.
• GLP-1 receptor agonists are diabetes and weight-loss medicines, and the oral small-molecule versions can reach deep brain targets and are cheaper to produce than peptide injectables.
• The findings are preclinical, supported by multiple NIH institutes, and not an FDA clinical assessment, with researchers planning follow-up tests on addiction and comparisons of compound-specific side effects such as nausea versus reduced food motivation.